Oral Hyaluronic Acid for Knee Osteoarthritis: The Absorption Question and the Meta-Analytic Effect

Hyaluronic acid is best known as an injectable viscosupplement for osteoarthritis and a topical hydrator in skin care. Oral hyaluronic acid supplements have historically been dismissed on the grounds that a polysaccharide of molecular weight 1,000 to 2,000 kDa cannot be absorbed intact through the gut wall. The pharmacokinetic and clinical picture has shifted in the past decade as low-molecular-weight (LMW) HA preparations have been studied, and a meaningful — if modest — clinical signal has emerged for knee osteoarthritis.

Pharmacokinetics: LMW HA does reach tissues

Balogh and colleagues 2008 fed 14C-labeled hyaluronic acid to rats and dogs and demonstrated absorption of intact HA and metabolic fragments via the lymphatic system, with measurable accumulation in joint tissues 24 to 72 hours after dosing [1]. Human pharmacokinetic studies are less direct but consistent: serum HA rises measurably after oral dosing of LMW preparations of 80 to 300 kDa, with the magnitude depending on molecular weight and formulation. The "it cannot be absorbed" argument was based on extrapolation from high-MW HA. LMW HA absorption is partial but real.

Knee OA trials: small but consistent

Tashiro and colleagues 2012 randomized 60 Japanese adults with knee OA to 200 mg/day of LMW HA or placebo for 12 months and reported greater WOMAC pain reduction in the HA arm, with effect emerging after eight weeks [2]. Nelson and colleagues 2015 conducted a 90-day RCT in 40 adults with knee OA and reported WOMAC and quality-of-life improvement with 80 mg/day of an oral HA formulation [3]. A 2020 meta-analysis by Oe and colleagues pooled 13 RCTs and concluded that oral HA produced a small but statistically significant improvement in OA symptom scores compared with placebo, with effect sizes roughly half those of intra-articular HA injections [4]. The pooled effect is modest and skewed toward Japanese trials.

Skin: a parallel evidence base

Oral HA has a separate evidence base for skin hydration, with 8 to 12-week RCTs showing improvement in stratum corneum water content and reduction in fine wrinkles at doses of 120 to 240 mg/day [5]. The skin effects appear earlier than joint effects, consistent with HA fragments serving as substrate for endogenous HA synthesis by dermal fibroblasts.

Why molecular weight matters

HA fragments below 50 kDa appear to be absorbed and may have pro-inflammatory signaling via TLR4. LMW HA in the 100 to 300 kDa range appears to be the optimal compromise between absorption and avoiding the pro-inflammatory fragments. High-MW HA (above 1,000 kDa) is poorly absorbed and largely fermented by gut microbes. Supplement labels rarely specify molecular weight, which makes product comparison difficult. Products marketed for joint health and that cite the Tashiro or Nelson trials should specify the molecular weight in their formulation documentation.

Comparing to alternatives

For knee OA pain, evidence-based options with stronger effect sizes include exercise therapy, weight loss in overweight patients, topical NSAIDs, and intra-articular corticosteroid or HA injection. Among oral supplements, glucosamine sulfate has a larger trial base (with mixed results), and avocado-soybean unsaponifiables and curcumin formulations have moderate evidence. Oral HA sits in a "consider as adjunct" category — small effect size, modest cost, low side-effect profile. It should not displace exercise and weight management.

Safety

Oral HA has been remarkably well tolerated in trials, with no consistent adverse-effect signal. The major theoretical concern relates to its effects on cancer biology — HA-CD44 signaling is relevant to several tumor types — but no clinical evidence suggests increased cancer risk from oral supplementation. Pregnancy and lactation data are insufficient.